65,437 trials
HIV Infection
Primary: Incidence Rates of AIDS - Defining Illness, Serious Non-AIDS Defining, Cardiovascular, Renal, Hepatic Event, or Death — 0.21; 0.31 New cases per 100 person - years…
Type 2 Diabetes Mellitus · Hypertension
Primary: Reduction in Albuminuria — -5.5; -6.7 percentage of UACR change
Atherosclerosis
Primary: Mean Circulating High Sensitivity C- Reactive Protein (Hs-CRP) Levels at Week 52. — 1.034; 0.913 mg per litre (mg/L) — p=0.348
Insomnia · Chronic Pain
Primary: Insomnia Severity Index (ISI) — 19.84; 16.04 units on a scale
Irritable Bowel Syndrome With Constipation · Chronic Constipation
Primary: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 65; 389; 454 Participants
Stroke, Acute · Neurological Impairment
Primary: Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period. — 59.8; 64.7 percentage of participants — p=0.52
Sleep Apnea, Obstructive · Diabetes Mellitus
Primary: Absolute Change in Brachial Artery Flow-mediated Dilation (FMD). — 2.26; 1.59 percentage of brachial artery diameter
Pain
Primary: Time for Subject to Reach Pain Threshold — 16.1; 16.0; 15.0; 14.8 seconds
Colorectal Cancer
Primary: Difference Between Progressive and High-Fidelity Groups on Clinical Colonoscopy Peformance (JAG/DOPS) — 68.2; 59.0; 68.3; 59.1 units on a scale
Influenza
Primary: Number of Subjects With Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 40 Participants
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 10; 19; 5; 13 Participants
Tumors
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 2 Participants
Asthma · Chronic Obstructive Pulmonary Disease COPD
Primary: Safety and Tolerability of AZD7594 by Assessment of the Number of Participants With Adverse Events — 3; 1; 1; 5 Pariticpants
Healthy Volunteers With Ileostomy
Primary: Ceftriaxone Concentration in Intestinal Chyme Period 1 — 0.00; 0.00; 5.60; 150.90 ug/mL
MPS 7 · Sly Syndrome · Mucopolysaccharidosis
Primary: European Union (EU) and Rest of World: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate (DS) at UX003 Treatment Week 24 — -64.82…